Andreas Cerny

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10469247/publications.pdf

Version: 2024-02-01

29 papers

3,467 citations

331670
21
h-index

26 g-index

29 all docs 29 docs citations

times ranked

29

4044 citing authors

#	Article	IF	CITATIONS
1	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology, 2010, 138, 1338-1345.e7.	1.3	1,056
2	Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology, 1999, 30, 595-601.	7.3	412
3	CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. European Journal of Immunology, 2000, 30, 2479-2487.	2.9	297
4	Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology, 2009, 51, 655-666.	3.7	247
5	IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. Journal of Experimental Medicine, 2013, 210, 1109-1116.	8.5	193
6	Molecular Mimicry of Human Cytochrome P450 by Hepatitis C Virus at the Level of Cytotoxic T Cell Recognition. Journal of Experimental Medicine, 1999, 190, 169-176.	8.5	144
7	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 2012, 143, 1244-1252.e12.	1.3	142
8	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology, 2012, 55, 384-394.	7.3	138
9	Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nature Communications, 2014, 5, 5699.	12.8	117
10	Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. Journal of Hepatology, 2011, 55, 529-535.	3.7	98
11	Hepatitis C virus and the immune system: a concise review. Reviews in Medical Virology, 2005, 15, 235-268.	8.3	84
12	Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Reviews in Medical Virology, 2003, 13, 361-371.	8.3	63
13	A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C. PLoS ONE, 2012, 7, e40159.	2.5	60
14	Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. PLoS ONE, 2013, 8, e64053.	2.5	59
15	Increased Cytotoxic T-Lymphocyte Epitope Variant Cross-Recognition and Functional Avidity Are Associated with Hepatitis C Virus Clearance. Journal of Virology, 2008, 82, 3147-3153.	3.4	55
16	Inductionin vitro of a primary human antiviral cytotoxic T cell response. European Journal of Immunology, 1995, 25, 627-630.	2.9	51
17	Cytotoxic T Lymphocytes Derived from Patients with Chronic Hepatitis C Virus Infection Kill Bystander Cells via Fas-FasL Interaction. Journal of Virology, 2004, 78, 2152-2157.	3.4	50
18	Perspectives: towards a peptide-based vaccine against hepatitis C virus. Molecular Immunology, 2001, 38, 475-484.	2.2	45

#	Article	IF	CITATIONS
19	A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine, 2004, 23, 58-68.	3.8	45
20	A systematic review and metaâ€analysis of <scp>HCV</scp> clearance. Liver International, 2017, 37, 1431-1445.	3.9	37
21	Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro. Hepatology, 2001, 33, 1282-1287.	7.3	30
22	Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. Journal of Autoimmunity, 2019, 102, 89-95.	6.5	16
23	A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virusâ€coinfected patients. Hepatology, 2016, 64, 1462-1472.	7.3	15
24	Stable human lymphoblastoid cell lines constitutively expressing hepatitis C virus proteins. Journal of General Virology, 2005, 86, 1737-1746.	2.9	6
25	Pathogenetic relevance of LKM-3 autoantibodies in chronic hepatitis D. Lancet, The, 1994, 344, 1369-1370.	13.7	3
26	Cell lines that allow regulated expression of HCV proteins. , 2003, , 175-186.		3
27	Viral crosstalk: Who gets to say what first?. Hepatology, 2002, 35, 1540-1543.	7.3	1
28	Allergy to antibacterials: the problem with beta-lactams and sulfonamides., 1998, 7, S23-S36.		0
29	Sudden Abdominal Pain and Jaundice in a Young Man. Hospital Practice (1995), 1998, 33, 139-143.	1.0	0